secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001447362-23-000127
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences Q2 revenue $50.1M (+44% YoY); raises FY 2023 guidance to at least $180M
--------------------------------------------------------------------------------

- Q2 revenue $50.1M (+44% YoY); adjusted revenue $50.2M (+47%).
- Total test reports 16,820 (+52%); DecisionDx-SCC +99%, TissueCypher +311%, IDgenetix +224%.
- Net loss $(18.8)M includes $12.8M stock comp; adjusted EBITDA improves to $(5.3)M from $(11.2)M.
- Raises 2023 revenue guidance to at least $180M from prior $170-180M.
- Cash and investments $225.5M; net operating cash use improved to $3.8M from $9.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736223000127/0001447362-23-000127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736223000127/cstl-20230802.htm
  HTML page:      https://secwatch.observer/filing/0001447362-23-000127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer